Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0

Rheumatology

Volumn 50, Issue 1, 2011, Pages 85-92

  Carmona, Loreto ^a   Descalzo, Miguel A ^a   Ruiz Montesinos, Dolores ^b   Manero Ruiz, Francisco J ^c   Perez Pampin, Eva ^d   Gomez Reino, Juan J ^d  

^a UNIDAD DE INVESTIGACIÓN   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d Instituto de Salud Carlos III   (Spain)

Author keywords

Effectiveness; Off label; Registry; Rheumatic diseases; Safety

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ADVERSE OUTCOME; ANKYLOSING SPONDYLITIS; ARTICLE; BEHCET DISEASE; CHRONIC DISEASE; CHRONIC IMMUNE MEDIATED DISEASE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE REGISTRY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOPATHOLOGY; INFECTION; INFESTATION; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; OFF LABEL DRUG USE; POLYARTHRITIS; POLYMYOSITIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SAPHO SYNDROME; SCLERODERMA; SKIN DISEASE; SOFT TISSUE DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VASCULITIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; OFF-LABEL USE; REGISTRIES; RHEUMATIC DISEASES; RISK ASSESSMENT; SPAIN; STATISTICS AS TOPIC; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79951719602     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq207     Document Type: Article

References (27)

1. Efthimiou P. Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications. Semin Arthritis Rheum 2006;36:168-72.
2. Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg 2005;9:296-302.
3. Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol 2007;56:e55-79.
4. Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 2006;100:2053-9.
5. Atzeni F, Sarzi-Puttini P, Doria A, Iaccarino L, Capsoni F. Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. Autoimmun Rev 2005;4:144-52.
6. Booth A, Harper L, Hammad T et al. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004;15:717-21.
7. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166:1021-6.
8. Bennett WM. Off-label use of approved drugs: therapeutic opportunity and challenges. J Am Soc Nephrol 2004;15: 830-1.
9. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48: 2122-7.
10. Meddra maintenance and support services organization. http://www.Meddramsso.Org (21 March 2010, date last accessed).
11. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007; 26:2389-430.
12. Ramos-Casals M, Brito-Zeron P, Munoz S, Soto MJ. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine 2008;87:345-64.
13. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 2009;11:R109.
14. Marie I. [Infections in polymyositis and in dermatomyositis]. Presse Med 2009;38:303-16.
15. Marie I, Hachulla E, Cherin P et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 2005;53:155-65.
16. Juarez M, Misischia R, Alarcon GS. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Rheum Dis Clin North Am 2003;29: 163-84.
17. Alarcon GS. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Infect Dis Clin North Am 2006;20:849-75.
18. Vastert SJ, Kuis W, Grom AA. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol 2009;23:655-64.
19. Giannini EH, Ilowite NT, Lovell DJ et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009;60:2794-804.
20. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004;31:2071-5.
21. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52:1766-72.
22. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005;52:1794-803.
23. Lequerre T, Quartier P, Rosellini D et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008;67:302-8.
24. Yokota S, Imagawa T, Mori M et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006.
25. Mima T, Nishimoto N. Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol 2009;21:224-30.
26. Carmona L, Hernandez-Garcia C, Vadillo C et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003;30:1436-9.
27. Gomez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57: 756-61.